Rituximab is a B-cell-depletion monoclonal antibody that is used to treat rheumatoid arthritis and other diseases. The chimeric structure of rituximab comprises human IgG 1 and kappa-chain constant regions and heavy- and light-chain variable regions from a murine antibody to CD20. Thus, I presume that rituximab could be used to deplete mouse CD20+ B cells. I also read some papers which use rituximab in mice before, but no figures about B cells after depletion were shown.
I used different doses of rituximab, and the drug was injected into C57BL/6 mice intravenously or intraperitoneally. One week after administration, blood, lymph nodes, and the spleen were collected and the number and percentage of CD19+B cells were evaluated. But no difference was observed between administrated and control groups.
Has anybody used rituximab to deplete mouse B cells before? Do I need to change a mouse CD20 mAbs rather than using rituximab if I want to deplete mice B cells?
Dear Echo Zhu ,
I am citing a sentence from the below article:
https://ashpublications.org/blood/article/90/6/2188/174699/IDEC-C2B8-Rituximab-Anti-CD20-Monoclonal-Antibody
>IDEC-C2B8 (=rituximab) is a chimeric MoAb containing human IgG1 (κ) heavy and light chain constant regions and murine variable regions from the murine anti-human CD20 MoAb IDEC-2B8 (murine IgG1, κ).
According to the sentence, rituximab derives from a mouse IgG1 directed against human CD20 but not against mouse CD20. So, I do not think you could presume that rituximab could be used to deplete mouse CD20+ B cells, though IDEC-C2B8 (=rituximab) and IDEC-2B8 might cross-react with mouse CD20.
If you wish to deplete mouse CD20+ cells, I could suggest the following product.
InVivoMAb anti-mouse CD20, clone MB20-11
https://bxcell.com/product/invivomab-anti-mouse-cd20-2/
- Badges
- Science topic
- Similar topics
- Entomology
- Resistance